KUPANDO
Current Employees Featured
Founder
More informations about "Kupando"
Kupando – Fighting Cancer and Infectious Diseases
A GAME-CHANGER. Kupando’s drug candidates are first-in-class, differentiated and competitive small molecules with the potential to transform the management of cancer and infectious diseases. The innate immune system is highly conserved. As such, its efficacy treating cancer …See details»
Kupando - Crunchbase Company Profile & Funding
Organization. Kupando . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Kupando is a …See details»
KUPANDO 2025 Company Profile: Valuation, Funding …
KUPANDO General Information Description. Operator of a biopharmaceutical company intended to develop immunostimulatory agents with the means to …See details»
Kupando raises €13 million in Series A funding round
Sep 26, 2022 Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to …See details»
News-20220926 - Remiges Ventures
Sep 26, 2022 Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses …See details»
Kupando GmbH - VentureRadar
Kupando is a pioneering biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity for use in oncology and infectious diseases. Its drug candidate …See details»
Kupando - Products, Competitors, Financials, Employees, …
Kupando is a biopharmaceutical company focused on developing TLR 4/7 agonists to stimulate innate immunity in the domains of oncology and infectious diseases. The company's main …See details»
Kupando raises €13M in funding round led by Remiges Ventures
Sep 26, 2022 Kupando says it will use the funds to complete IND-enabling work and to initiate the clinical development its lead candidate, KUP101 in a solid tumor indication. Liposomal …See details»
Kupando - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Sep 26, 2022: Series A - …See details»
Kupando GmbH Overview | SignalHire Company Profile
Organization Website: kupando.com : Kupando GmbH industries Biotech: Headquarters Location: Willy-Brandt Platz 2, Schönefeld, Brandenburg, 12529 DE Willy-Brandt Platz 2, Schön...See details»
Kupando - Remiges Ventures
Sep 26, 2022 Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. Kupando is a …See details»
Kupando - Raised $12.6M Funding from 9 investors - Tracxn
Mar 23, 2025 Kupando has raised a total funding of $12.6M over 1 round from 9 investors. Investors include HTGF, Brandenburg Capital and 7 others. Their latest funding round was of …See details»
Kupando - Crunchbase
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.See details»
Kupando Raises €13 Million in Series A Funding Round - Biotech …
Sep 26, 2022 Kupando, a biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, closes a Series A …See details»
Kupando - HTGF
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small …See details»
Kupando Raises €13M in Series A Funding - finsmes.com
Sep 26, 2022 Kupando, a Schoenefeld, Germany-based biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, …See details»
Kupando raises €13 million in Series A funding round | HTGF
Schönefeld/Berlin, 26. September 2022 – Kupando, a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious …See details»
Kupando GmbH - Schönefeld, Germany - bionity.com
KUPANDO is a pioneering Berlin-based biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity. Our Mission is to provide, not only a safe but also …See details»
Press Releases Archive - Kupando
Sep 26, 2022 Kupando raises €13 million in Series A funding round. by Bettina Hanika | Sep 26, 2022 | Press Releases. Financing led by Remiges Ventures, co-led by LifeCare Partners, with …See details»
Kupando - Contacts, Employees, Board Members, Advisors & Alumni
Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.See details»